Zohran Mamdani, a familiar name in New York’s political scene, is stirring things up. If he lands the mayor’s seat, he’s thinking about yanking New York City pension funds out of Israel.

During a Sunday chat on CBS2 New York’s “The Point with Marcia Kramer,” Mamdani didn’t hold back. “We shouldn’t have funds tangled up with anything against international law,” he put it bluntly. You can catch more of his thoughts here.

Mamdani’s running as the Democratic mayoral candidate and he’s got eyes on divesting from Israeli bonds. If you’ve been around the New York block, you might recall that Brad Lander, the current comptroller, is kind of on the same page. He stopped reinvesting in those bonds when they hit maturity. Lander’s move was a game-changer, considering the city had poured money into those bonds since the 1970s.

subheadings
Divestment Drama

Comptroller Lander, who Mamdani practically calls a pal, shut the door on reinvesting those bonds. Yet, he’s also said the city keeps over $300 million tied up in Israeli firms. That’s a chunk of change.

Mamdani’s statement rattled some cages. Pension funds still cozy up to some Israeli companies, even as bond investments dried up. But Mamdani argues, “Direct involvement is key.” He insists that funneling into Israel bonds screams something about our city’s values. Want to know more about that viewpoint? Check out NY Times.

A Cautious Caller

It’s worth mentioning that Mamdani’s stance isn’t all-encompassing. While he chants “BDS” at pro-Palestinian gatherings, he’s not pushing to cut ties with all Israeli firms. It’s a delicate dance for him.

Political Tug-of-War

Investments and pensions get caught in political crossfire, especially with Manhattan Borough President Mark Levine in the comptroller race. Levine’s been adamant about backing Israel bonds. He wants to team up with other pension trustees, chasing solid, stable returns. His spokesperson, Annabel Lassally, reiterated that recently.

Voices and Barks

Former City Comptroller Scott Stringer had no qualms calling out Mamdani’s proposed divestment as a “mistake.” He believes Israel bonds have been a sturdy bet since the disco era. Israel Bonds’ CEO, Dani Naveh, also piped in, noting a massive $5.5 billion in investments since October 7th. More deets on this sentiment can be found here.

The Bottom Line

So, if Mamdani wears the mayoral crown, there’s a potential showdown. With his appointees on pension boards, he could butt heads with the comptroller over Israel bonds. But one thing’s certain: pensions and politics in New York are anything but dull.

Interested in more local breakdowns? Stay tuned on NY1.

The post Zohran Mamdani Aims to Redirect NYC Pension Funds Away from Israeli Investments if Elected Mayor appeared first on Kingston Global Tokyo Japan.

Well, gather ’round, folks! If you’re into biotech and investment, I’ve got a juicy tidbit for you. Everyone’s favorite players in the antibody game, ImmunoPrecise Antibodies (IPA), are stepping into the bright lights of New York City for a splashy event. That’s right, they’re hitting up H.C. Wainwright’s 26th Annual Global Investment Conference.

What You Need to Know

IPA’s participation in this prestigious event isn’t a small deal. For those unfamiliar, ImmunoPrecise Antibodies is a big name in the field of antibody discovery. Their proprietary technologies, especially tailored for rapid and customized therapeutic antibody development, have got quite the reputation.

The Conference

Now, you may be wondering about this event taking place in the heart of NYC. Hosted by H.C. Wainwright, it’s one of the most significant gatherings on the investment calendar. Investors, industry leaders, and visionary creators mingle under one roof. It’s like a biotech Mardi Gras!

Why It Matters

ImmunoPrecise’s involvement signals something crucial. In a city that never sleeps, they’re making connections and showcasing their innovative edge. Networking here isn’t just about handshakes; it’s about deals, collaborations, and opportunities.

Featured Highlights

• Therapeutic Antibodies: They’re diving deep into bespoke solutions for infectious diseases and cancer.

• Cutting-Edge Technology: Their B cell select and single-cell VH/VL pairing technologies are causing quite the stir.

The Buzz

We know the skepticism around conferences and talks. But hey, keep an eye on the market shifts post-event. Stocks could rally, deals could roll, and innovations might just leap from paper to reality.

Related Tables

They’re Not Alone

Other heavyweights are also part of the lineup. Expect a formidable representation from top-tier biotech firms and investment banks. Think of it as the Avengers assembly, but with less spandex and more lab coats.

Are You in NYC?

For the fortunate souls in New York, this could be your golden ticket. Perhaps you’re just steps away from the next big breakthrough in medical research. Imagine rubbing shoulders with the very folks shaping the future of healthcare!

Final Thoughts

So what’s the takeaway? IPA’s participation isn’t just a meeting. It’s a move, a strategy, a doorway to endless possibilities. This conference acts like a melting pot where science meets finance, and boy, are we in for some fireworks!

Remember, in New York, it’s not just about making it but about leading the way. Keep an ear out and an eye peeled. You never know what might unfold next!

Read more on Business Wire

The post ImmunoPrecise Antibodies to Join H.C. Wainwright’s 26th Annual Global Investment Event in NYC appeared first on Kingston Global Tokyo Japan.